Club Insider

End of 2018 Update From ALS TDI

  • For this article, Log In to:
  • View eVersion View eVersion | Download PDF Download PDF

ALS TDICAMBRIDGE, MA - As our team works through the last hours of 2018, we wanted to take the time to reflect on some of the ALS Therapy Development Institute's notable accomplishments from the year.

We advanced AT-1501 from the research lab and into clinical trials, an unprecedented achievement.

We now have over 500 people living with ALS enrolled in our Precision Medicine Program, an initiative that, among other things, may speed up and decrease the cost of all ALS clinical trials.

We made strides toward developing and validating more models of ALS in which to test treatments, including C9orf72 repeat expansion mutations.

We screened more potential treatments in our labs than anywhere else in the world.

Despite all the progress made throughout the year, we know that 2018 also brought incredible loss to families and people battling this disease. Loss of independence, loss of abilities and the devastating loss of loved ones. Not a day goes by at ALS TDI that we don't mourn someone who has passed and talk to others who are currently fighting. These conversations motivate us to keep up the momentum of 2018 and try to do even more in 2019.

Recently, you may have read an email from Andrea Peet who stressed that, while we are more hopeful than ever, the job is not done yet. Heading into 2019, we are laser focused on building on all the work we have done so far, discovering and developing more treatments, enrolling more participants in the PMP and validating more models of the disease. We truly can't do any of this without your help.

Your 100% tax-deductible donation will help to get more potential treatments, like AT-1501, to people who desperately need them.

To donate, go to www.als.net/donate.

Thank you and Happy New Year!

Dr. Steve Perrin
CEO
The ALS Therapy Development Institute

To view the full article, please Log In.

If you are not a Paid Subscriber, we welcome you to Subscribe Now.

Back to Edition